Arrowhead Reports Fiscal 2014 First Quarter Financial Results

  Arrowhead Reports Fiscal 2014 First Quarter Financial Results

              - Conference Call Today at 4:30 p.m. Eastern Time

Business Wire

PASADENA, Calif. -- February 4, 2014

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company
developing targeted therapeutics, today announced financial results for its
fiscal 2014 first quarter ended December 31, 2013. The company is hosting a
conference call at 4:30 p.m. Eastern time to discuss results. To participate,
please dial 877-300-8521 (toll free from the US), 855-669-9657 (toll free from
Canada), or 412-317-6026 (for international callers). Investors may also
access a live audio webcast of this conference call on the Company's website

A replay of the webcast will be available approximately one hour after the
conclusion of the call and will remain available for 90 days. An audio replay
will also be available approximately two hours after the conclusion of the
call and will be available for 30 days. The audio replay can be accessed by
dialing 877-870-5176 (toll free from the US and Canada), or 858-384-5517 (for
international callers), and entering Event ID 10040388.

Fiscal 2014 First Quarter and Recent Company Highlights

  *Completed planned enrollment in a Phase 1 clinical trial of the ARC-520
    candidate against chronic hepatitis B infection in 36 healthy volunteers;
  *Strengthened the balance sheet with an equity offering with $60 million in
    net proceeds;
  *Presented data at the AASLD Liver Meeting suggesting that in a chimpanzee
    chronically infected with HBV, ARC-520 may have induced a therapeutic
    immunological flare, which is thought to be part of a cascade of events
    that after longer exposure may lead to functional cure;
  *Submitted application to the Hong Kong Department of Health requesting
    permission to begin a Phase 2a trial of ARC-520 in chronic hepatitis B
  *Presented unblinded Phase 1 data at HepDART 2013 indicating that ARC-520
    was generally safe and well tolerated at all six dose levels studied, with
    no differences in adverse event frequency and severity between treatment
    and placebo groups.

Selected Fiscal 2014 First Quarter Financial Results

Net loss attributable to Arrowhead for the quarter was $10.6 million, or $0.28
per share based on 37.7 million weighted average shares outstanding. This
compares with a net loss attributable to Arrowhead of $4.6 million, or $0.33
per share based on 14.1 million weighted average shares outstanding, for the
quarter ended December 31, 2012.

Total operating expenses for the quarter ended December 31, 2013 were $7.1
million, compared to $5 million for the quarter ended December 31, 2012.
Research and development related expenses were $4.5 million and $1.7 million
for general and administrative expenses.

Net cash used in operating activities for the quarter was $7 million, compared
with $3.8 million in the prior year period.

The company’s cash and investments of cash were $85.5 million at December 31,
2013, compared to $29.8 million at September 30, 2013. The increase in the
cash balance reflects $60 million from financings during the quarter, plus
cash inflow from exercise of warrants and stock options of $2.8 million.

Common shares outstanding at December 31, 2013, were 39 million, and 49.7
million assuming conversion of preferred stock outstanding.

About ARC-520

Approximately 350 million people worldwide are chronically infected with the
hepatitis B virus. Chronic HBV infection can lead to cirrhosis of the liver
and is responsible for 80% of primary liver cancers globally. Arrowhead’s
RNAi-based candidate ARC-520 is designed to treat chronic HBV infection by
reducing the expression and release of new viral particles and key viral
proteins. The goal is to achieve a functional cure, which is an immune
clearant state characterized by hepatitis B s-antigen negative serum with or
without sero-conversion. The siRNAs in ARC-520 intervene at the mRNA level,
upstream of where nucleotide and nucleoside analogues act. In transient and
transgenic mouse models of HBV infection, a single co-injection of Arrowhead’s
DPC delivery vehicle with cholesterol-conjugated siRNA targeting HBV sequences
resulted in multi-log knockdown of HBV RNA, proteins and viral DNA with long
duration of effect. In a chimpanzee chronically infected with HBV and high
viremia and antigenemia, ARC-520 induced rapid reductions of 90-95% in HBV
DNA, e-antigen, and s-antigen, which did not return to baseline until study
day 43, 43, and 71, respectively. Data also suggested that a therapeutic
immunological flare occurred, which is thought to be part of a cascade that
under chronic therapy may lead to HBsAg seroconversion and functional cure.
Arrowhead has completed enrollment in a phase 1 single ascending dose study in
normal volunteers, which the company expects to follow with a phase 2a study
in chronic HBV patients.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a biopharmaceutical company developing
targeted RNAi therapeutics. The company is leveraging its proprietary drug
delivery technologies to develop targeted drugs based on the RNA interference
mechanism that efficiently silence disease-causing genes. Arrowhead
technologies also enable partners to create peptide-drug conjugates that
specifically home to cell types of interest while sparing off-target tissues.
Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus
and partner-based programs in obesity and oncology.

For more information please visit, or follow
us on Twitter @ArrowRes. To be added to the Company's email list to receive
news directly, please send an email to

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995. These statements are based upon our current expectations and speak
only as of the date hereof. Our actual results may differ materially and
adversely from those expressed in any forward-looking statements as a result
of various factors and uncertainties, including our ability to finance our
operations, the future success of our scientific studies, our ability to
successfully develop drug candidates, the timing for starting and completing
clinical trials, rapid technological change in our markets, and the
enforcement of our intellectual property rights. Arrowhead Research
Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly
Reports on Form 10-Q discuss some of the important risk factors that may
affect our business, results of operations and financial condition. We assume
no obligation to update or revise forward-looking statements to reflect new
events or circumstances.


Arrowhead Research Corporation
Vince Anzalone, CFA
The Trout Group
Lauren Glaser
Press spacebar to pause and continue. Press esc to stop.